Objective-Prenatal deletion of the type II transforming growth factor-β (TGF-β) receptor (TBRII) prevents normal vascular morphogenesis and smooth muscle cell (SMC) differentiation, causing embryonic death. The role of TBRII in adult SMC is less well studied. Clarification of this role has important clinical implications because TBRII deletion should ablate TGF-β signaling, and blockade of TGF-β signaling is envisioned as a treatment for human aortopathies. We hypothesized that postnatal loss of SMC TBRII would cause aortopathy. Approach and Results-We generated mice with either of 2 tamoxifen-inducible SMC-specific Cre (SMC-CreER T2 ) alleles and homozygous floxed Tgfbr2 alleles. Mice were injected with tamoxifen, and their aortas examined 4 and 14 weeks later. Both SMC-CreER T2 alleles efficiently and specifically rearranged a floxed reporter gene and efficiently rearranged a floxed Tgfbr2 allele, resulting in loss of aortic medial TBRII protein. Loss of SMC TBRII caused severe aortopathy, including hemorrhage, ulceration, dissection, dilation, accumulation of macrophage markers, elastolysis, abnormal proteoglycan accumulation, and aberrant SMC gene expression. All areas of the aorta were affected, with the most severe pathology in the ascending aorta. Cre-mediated loss of SMC TBRII in vitro ablated both canonical and noncanonical TGF-β signaling and reproduced some of the gene expression abnormalities detected in vivo. Conclusions-SMC TBRII plays a critical role in maintaining postnatal aortic homeostasis. Loss of SMC TBRII disrupts TGF-β signaling, acutely alters SMC gene expression, and rapidly results in severe and durable aortopathy. These results suggest that pharmacological blockade of TGF-β signaling in humans could cause aortic disease rather than prevent it.
T ransforming growth factor-β (TGF-β) signaling in cultured smooth muscle cells (SMCs) or SMC precursors regulates cell growth and migration. TGF-β signaling also promotes synthesis of SMC differentiation markers and extracellular matrix proteins. [1] [2] [3] [4] [5] [6] Loss of SMC TGF-β signaling during development prevents SMC differentiation and matrix synthesis, causing severe vascular abnormalities and embryonic lethality. [7] [8] [9] [10] Without question, SMC TGF-β signaling is essential for normal embryogenesis. However, the role of TGF-β signaling in adult aortic SMC is less well established, and the critical question of whether SMC TGF-β signaling is salutary or pathogenic remains controversial. Salutary roles for adult SMC TGF-β signaling are suggested by animal studies showing that cardiovascular overexpression of TGF-β increases matrix synthesis and prevents aneurysm growth and that systemic blockade of TGFβ exacerbates angiotensin II-induced aortic aneurysms. [11] [12] [13] [14] [15] In contrast, pathogenic effects of adult SMC TGF-β signaling are suggested by apparent increases in aortic SMC TGF-β signaling in association with human aortopathies (Marfan, Loeys-Dietz, Shprintzen-Goldberg syndromes, familial thoracic aortic aneurysms, and dissections associated with mutations in TGFB2) and in mouse models of these diseases. [16] [17] [18] [19] [20] These reports, along with evidence that TGF-β antagonism achieved by injection of a neutralizing anti-TGF-β antibody could prevent aortopathy in Fbn1-deficient mice, 17 spawned the hypothesis that TGF-β signaling in aortic SMC is pathogenic, and prompted clinical trials aimed at preventing aortopathy with a drug (Losartan) that is hypothesized to block TGF-β signaling. [21] [22] [23] 
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We used genetically modified mice to test whether disruption of physiological TGF-β signaling by SMC-targeted deletion December 2015 of the type II TGF-β receptor (TBRII) affects aortic homeostasis. We found that SMC TBRII loss has profound effects on aortic structure, SMC gene expression, aortic extracellular matrix accumulation, and cell proliferation. While this work was being carried out, another group reported results of similar experiments. 24 Here, we extend those findings, using a different conditional Tgfbr2 allele 25 and 2 inducible SMC-specific Cre recombinase strains (Acta2-CreER T2 and Myh11CreER T2 ). 26, 27 We also report in vitro data suggesting that cell-autonomous alterations in SMC TGF-β signaling are the primary cause of aortopathy in mice with SMC-specific loss of TBRII. Our results reveal a critical role for adult aortic SMC TGF-β signaling and suggest a cautious approach toward pharmacological strategies that block SMC TGF-β signaling in humans.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Similar Cre Recombinase Activity in 2 Lines of SMC-CreER T2 Mice
We compared the inducibility, efficiency, and tissue specificity of Cre recombinase activity in 2 lines of mice with SMC-targeted inducible Cre alleles (Acta2-CreER T2 and Myh11-CreER T2 ). We generated mice that were hemizygous for 1 of these 2 alleles and either hemizygous or homozygous for the R26R-reporter allele. Mice from each line were injected with tamoxifen (n=6) or vehicle (n=2-5). As additional controls, CreER T2 0/0 /R26R + littermates in both lines were injected with tamoxifen (n=3-4). Tissues were harvested 5 days to 8 weeks later; time to harvest was identical in experiments comparing the 2 SMC-Cre lines and similar results were obtained with R26R +/0 and R26R +/+ mice. As judged by X-Gal stain, after injection of tamoxifen both alleles recombined R26R specifically and efficiently in both vascular and visceral SMC ( Figure I in the online-only Data Supplement). Low-level SMC-specific tamoxifen-independent background Cre activity (ie, rare blue medial cells) was detected in vehicle-injected CreER T2 +/0 mice of both lines ( Figure I in the online-only Data Supplement). High-level background SMC-specific Cre activity (ie, numerous blue cells) was present in the muscular layer of the urinary bladder of CreER T2 +/0 R26R + mice of both lines (Figure I in the online-only Data Supplement). Low-level background Cre activity was also detected by polymerase chain reaction of tail DNA ( Figure II in the online-only Data Supplement). Despite this leakiness, expression from both SMC-Cre alleles appeared SMCrestricted both with and without tamoxifen: no nonvascular blue cells were seen grossly or microscopically in SMC poor tissues, including heart and skeletal muscle. There was no Cre activity (no blue cells) in tamoxifen-injected SMC-CreER T2 0/0 R26R + mice of either line.
To more precisely compare SMC-Cre activity in the 2 lines, we measured LacZ mRNA in the aortic media (see below) of tamoxifen-treated Cre +/0 R26R +/+ mice of both lines. Expression of LacZ mRNA in the 2 lines was equivalent and far above the background levels in tamoxifen-injected Cre 0/0 R26R +/+ controls ( Figure III in the online-only Data Supplement). For the remainder of our experiments, we compared tamoxifen-treated Cre +/0 R26R +/+ Tgfbr2 flox/flox mice with tamoxifen-treated Cre 0/0 R26R +/+ Tgfbr2 flox/flox mice. This design compares Tgfbr2 null/null SMC to Tgfbr2 flox/flox SMC, eliminates concerns about background Cre activity, and controls for exposure to tamoxifen, an agent that affects the vasculature directly. [28] [29] [30] [31] [32] 
Measurement of TBRII Protein and Tgfbr2 mRNA in Aortic SMC
Because vascular Cre activity is limited to medial SMC ( Figure I in the online-only Data Supplement)-and because our primary goal is to determine the role of Tgfbr2 in SMCwe focused our biochemical analyses on aortic medial tissue. We accomplished this by removing the aortic luminal endothelium, separating the media from the adventitia ( Figure IV in the online-only Data Supplement), and extracting protein and RNA from the entire aortic media. Measurement of SMC markers in RNA extracted from either media or adventitia confirmed significant enrichment of SMC in medial tissue ( Figure V in the online-only Data Supplement). Injection of tamoxifen in Cre +/0 mice induced substantial reduction of TBRII protein in the aortic media of both lines ( Figure 1) . Surprisingly, however, when we measured Tgfbr2 mRNA using primers internal to the floxed Tgfbr2 exon 4 region, we found that aortic medial Tgfbr2 mRNA was either increased or unchanged in tamoxifen-injected Cre +/0 mice of both lines ( Figure VI in the online-only Data Supplement). To confirm that Cre had excised the expected region, we sequenced null allele amplicons produced by polymerase chain reaction of tail DNA. The amplicons contained discontinuous sequences of Tgfbr2 separated by a loxP site ( Figure II in the onlineonly Data Supplement), confirming Cre-mediated deletion of Tgfbr2. As an additional control, we used exon 2-specific primers to measure Tgfbr2 mRNA. Again, we found increased Tgfbr2 mRNA after tamoxifen injection, this time in Cre +/0 mice of both lines ( Figure VI in the online-only Data Supplement). These results suggest compensatory increases in Tgfbr2 mRNA, but loss of TBRII protein in SMC of tamoxifen-injected Cre +/0 mice.
Loss of TBRII in Aortic SMC Disrupts Aortic Structure
Six-week-old Cre +/0 and Cre 0/0 mice of both lines were injected with tamoxifen daily for 5 days, euthanized 4 or 14 weeks after the last injection, and their aortas examined grossly and Table II in the online only Data Supplement). Sectioning of segments of AscA, DTA, and AA of randomly selected subsets of mice revealed intramural hematomas (IMHs; defined as free red blood cells in the media; Figure 2H , 2J, and 2L) in 5 of 15 (33%) of Cre +/0 mice (both lines combined; results for each line are in Table II in the online only Data Supplement). Penetrating aortic ulcers (PAUs; defined as a break in the intima and media exposing the inner media to the lumen; Figure 2H ; Figures Table II in the online only Data Supplement). Neither IMH nor PAU were present in any Cre 0/0 mouse in either line (0 of 13; P=0.04 and P<0.0001, respectively; all Cre +/0 versus all Cre 0/0 mice). Rare, apparent aortic dissections (defined as an extended separation of medial layers containing a large pool of blood) were found in mice in this study and in a pilot group of mice not otherwise reported here ( Figure 2J ; Figure VIIIB and VIIIE in the online-only Data Supplement).
To determine whether aortic disease progressed over time, we examined aortas from mice euthanized 14 weeks after tamoxifen injection. At this time point, PAUs were present in 13 of 14 (93%) Cre +/0 mice of both lines (almost exclusively in the AscA) and in 0 of 14 Cre 0/0 mice ( Table II in the online only Data Supplement; P<0.0001). On gross examination, aortic discoloration suggestive of hemorrhage was noted in 10 of 18 Cre +/0 mice (56%) of both lines (most commonly in the AscA and arch; Table II in the online only Data Supplement) and in 0 of 14 Cre 0/0 controls (P<0.002). Surprisingly, microscopic examination of aortic sections of these mice (including all 10 aortas judged on gross examination to have aortic hemorrhage) revealed no free red blood cells in the aortic wall. To determine whether the absence of red cells in aortic media of Cre +/0 mice 14 weeks after tamoxifen injection was because of partial resolution of IMH, we stained AscA sections with Prussian blue. Sections of AscA from 9 of 14 (64%) of Cre +/0 mice of both lines stained with Prussian blue compared with 0 of 14 AscA of Cre 0/0 controls (P=0.0006; Table II and Figure  VIIIC and VIIIF in the online-only Data Supplement). Four weeks after tamoxifen injection, Prussian blue staining was also present in 6 of 15 (40%) Cre +/0 mice of both lines and 0 of 13 controls (Table II in the online only Data Supplement; P<0.02). Therefore, aortic hemorrhage begins shortly after deletion of Tgfbr2, resolves, and does not seem to recur.
Aortic wall morphology, evaluated on transverse sections, was abnormal in Cre +/0 mice of both lines. Four weeks after tamoxifen injection, the lengths of the internal elastic lamina and external elastic lamina of Cre +/0 aortas were increased marginally, if at all, compared with Cre 0/0 controls of both lines. However, aortic medial thickness and medial crosssectional area were increased in AscA, DTA, and AA of both lines (14%-39% and 14%-52%, respectively; Figure 3 ). All of these increases were significant for the Acta2-Cre line; increases of similar magnitude in the Myh11-Cre line were less uniformly significant, probably because of smaller group sizes (6 versus 7-9). Fourteen weeks after tamoxifen injection, the internal elastic lamina and external elastic lamina lengths of Cre +/0 aortas were significantly increased compared with Cre 0/0 controls (6%-32% and 6%-31%, respectively; Figure 4 ), and lumens seemed larger ( Figure 5 ; Figure IX in the online-only Data Supplement). However, increased medial thickness in Cre +/0 versus Cre 0/0 mice at 14 weeks (8%-21%) was less pronounced than at 4 weeks, and it was confined to the AscA and AA (Figure 4 ). In contrast, increases in medial area of Cre +/0 aortas were relatively larger at 14 versus 4 weeks (40%-60% versus Cre 0/0 controls) and they were also confined to the AscA and AA (Figure 4 ). Therefore, SMC Tgfbr2 deletion causes early medial thickening followed by vessel dilation and relative medial thinning. That is, Cre +/0 aortas dilate between 4 and 14 weeks, whereas their medial thickness changes relatively little (Cre +/0 medias thicken less from 4 to 14 weeks than Cre 0/0 medias). Medial area in 14- week Cre +/0 aortas is increased primarily because of a larger circumference, not increased thickness. Overall, morphological changes are far greater in the AscA and AA than in the DTA, especially at 14 weeks. Abnormal aortic morphology (eg, significantly increased internal elastic lamina and external elastic lamina lengths) was present even in the most caudal AA sections, taken at the level of the left renal artery. The infrarenal AA was not analyzed histologically.
Loss of TBRII in Aortic SMC Results in Elastin Damage, Increased Macrophage Markers, Cell Proliferation, and Matrix Accumulation
To further characterize aortic damage and potential healing responses after loss of SMC TBRII, we stained sections to detect elastin fibers, macrophage markers, cell proliferation, and extracellular matrix proteins. We measured elastin damage by counting elastic lamina breaks in AscA sections from both lines. Elastin breaks were 2-to 5-fold more frequent in Cre +/0 mice of both lines, at both time points ( Figure X in the online-only Data Supplement; P<0.01). In both lines, elastin breaks increased over time (P<0.01).
We assessed the presence of macrophage markers by staining aortic sections for Mac-2. For both lines, Mac-2 staining was rare in sections from Cre 0/0 mice but common in sections from Cre +/0 mice. The percentage of Mac-2-positive medial area was increased significantly in all 3 regions (3-to 8-fold; P<0.05 except for 14-week DTA and AA in the Myh11-Cre line; Figure XI in the online-only Data Supplement). Mac-2 staining was typically located near an area of medial damage/ hemorrhage, identified by the presence of PAU, IMH, or Prussian blue stain on adjacent slides. An independent measure of macrophage marker accumulation, CD68 mRNA, was 4-to 5-fold more abundant in extracts from Cre +/0 versus Cre 0/0 aortic media (P<0.01 for both lines; Figure 6 ).
We measured cell proliferation in the AscA by pulse labeling with BrdU just before the 4-week time point. For both lines, BrdU-positive nuclei were rare in Cre 0/0 aortas and significantly increased in Cre +/0 aortas (5-to 13-fold increases in total BrDU-positive nuclei; P≤0.01). BrdU-positive cells were most common in the adventitia, with fewer along the luminal surface and even fewer in the media ( Figure XII in the onlineonly Data Supplement).
Movat staining showed increased proteoglycan and collagen deposition in aortas of both lines of Cre +/0 mice at 4 and 14 weeks. Proteoglycan and collagen accumulation were predominantly in the adventitia and most evident in AscA sections ( Figure XIII in the online-only Data Supplement). An observer was blinded to genotype, given Movat-stained AscA sections from Cre +/0 and Cre 0/0 mice of both lines, and asked to assign Cre genotype based only on extent of blue-green staining indicative of proteoglycan accumulation. The observer correctly genotyped 21 of 28 of the mice euthanized 4 weeks after tamoxifen and 27 of 28 of the mice euthanized 14 weeks after tamoxifen (P=0.006 and P<0.0001, respectively).
We also stained sections from aortas of Acta2-Cre +/0 and Acta2-Cre 0/0 mice for versican, a proteoglycan that is regulated by TGF-β 33 and affects both SMC phenotype and tissue inflammation. 34, 35 Versican staining was significantly increased in AscA and AA at both 4 and 14 weeks (4 -47-fold, P<0.001). Versican staining was typically highest in regions with PAU and adjacent Mac-2 staining ( Figure XIV 
Loss of TBRII Alters Aortic SMC Gene Expression
To begin to identify the mechanisms through which loss of SMC TBRII affects the aorta, 4 weeks after tamoxifen treatment we isolated total aortic medial RNA and measured mRNA of several classes of genes: (1) genes involved in TGFβ signaling (Tgfbr1, Tgfbr3, Tgfb1, Tgfb2, Tgfb3, and Smad7);
(2) genes involved in maintaining the differentiated SMC phenotype (Acta2, Myh11, Tagln, Smtn, and Cnn1); (3) Genes involved in extracellular matrix metabolism (Lox, Loxl1, Col1a1, Mmp2, Mmp9, and Mmp12); (4) Canonical targets of TGF-β signaling (Ctgf and Serpine1); and (5) Other genes involved in aneurysm formation (Igf1 and Ace). 36 mRNA encoding Tgfbr3, Tgfb2, Tgfb3, and Smad7 were significantly increased after loss of TBRII in SMC from both lines (2-to 4-fold; P≤0.01 for all; Figure 6 ), Tgfb1 and Tgfbr1 mRNA were increased in Acta2-Cre +/0 mice (P<0.03) and unchanged in Myh11-Cre +/0 mice. Genes encoding SMC lineage markers (Acta2, Myh11, Tagln, Smtn, and Cnn1) were upregulated in both lines (2-to 4-fold; P<0.05 for all). Among genes involved in extracellular matrix metabolism, Loxl1 and Mmp2 were significantly upregulated in both lines (2-to 4-fold; P≤0.005 and P<0.04, respectively). Lox, Col1a1, Mmp9, and Mmp12 were either unchanged or divergent between the lines. Ctgf mRNA decreased significantly in Acta2-Cre +/0 mice 
TBRII Knockdown in Cultured Aortic SMC Abrogates Canonical and Noncanonical TGF-β Signaling
Aortic SMC from Acta2-Cre 0/0 Tgfbr2 flox/flox mice were established in culture and treated with either AdCMVCre or AdCMVNull. Treatment with AdCMVCre reduced TBRII protein by 95% (P=0.006; Figure 7A and 7B). After treatment of SMC with either AdCMVCre or AdCMVNull, we added recombinant mouse TGF-β1 (1 ng/mL) to the cells. Cre-mediated deletion of Tgfbr2 significantly decreased TGF-β1 activation of both canonical (p-Smad2) and noncanonical (p-ERK and p-P38) TGF-β signaling pathways (60%-90% reduction in peak levels; P<0.05 for all; Figure 7A , 7C-7E).
Loss of TBRII Alters Gene Expression in Cultured Aortic SMC
Cre-mediated loss of TBRII altered gene expression in cultured SMC in a pattern similar-although not identical-to that found in medial SMC of tamoxifen-treated SMC-CreERT2 +/0 mice ( Figure XV in the online-only Data Supplement). mRNA encoding Tgfb1 was significantly increased (2-fold; P<0.001), with trends toward increased expression of Tgfbr1, Tgfb2, and Tgfb3. mRNA encoding 3 of 4 SMC lineage markers were also increased (Myh11, Cnn1, and Tagln; 2-to 5-fold; P≤0.01). Levels of Mmp2 and Mmp9 mRNA were far higher in cells lacking TBRII (8-to 10-fold; P≤0.002).
Discussion
We used mice with inducible SMC-targeted Cre alleles and conditional Tgfbr2 alleles to delete TBRII in SMC and discover the consequences of loss of physiological SMC TGF-β signaling. Our major findings are (1) loss of TBRII in aortic SMC causes a major disruption of aortic wall structure within 4 weeks, including intramural hemorrhage, wall thickening, ulceration, elastolysis, matrix accumulation, evidence of macrophage infiltration, and increased cell proliferation; (2) at a later time point (14 weeks) aortas that lack SMC TBRII are dilated with relative medial thinning, progressive elastolysis, and evidence of persistent macrophage accumulation; (3) loss of TBRII in aortic SMC in vivo dramatically alters SMC expression of genes encoding proteins involved in TGF-β signaling, contractile function, and extracellular matrix metabolism; and (4) deletion of Tgfbr2 in cultured SMC rapidly alters expression of many of the same genes. Taken together, our results suggest that physiological TGF-β signaling plays a critical role in maintaining aortic homeostasis and that loss of physiological TGF-β signaling in SMC causes aortopathy that largely results from cell-autonomous effects on SMC.
We began this study by comparing 2 lines that express SMC-targeted inducible Cre recombinase. 26, 27 Lines of transgenic mice can lose both transgene activity and tissue specificity over time; 7,37 therefore, we characterized both lines Gene expression was measured by quantitative reverse transcriptase-mediated polymerase chain reaction, using RNA isolated from the aortic media. *P<0.05; **P<0.01; ***P<0.001 compared to Cre 0/0 controls. n = 9 to 10 for Acta2-Cre groups; n=6 for Myh11-Cre groups.
extensively. Both lines efficiently and specifically rearranged the R26R-reporter allele in SMC, with no detectable differences between them. Both lines also produced essentially identical phenotypes when crossed into Tgfbr2 flox/flox mice. Therefore, the theoretical concern that the Myh11-Cre allele must be used to avoid confounding Cre recombinase activity that could be present in non-SMC that express Acta2 38, 39 was not supported by our results. Others have also reported equivalent results with these 2 lines. 40 Importantly, in this other study as well as ours, Cre activity was induced by tamoxifen administration to mice without pre-existing vascular disease. The Acta2-Cre allele should probably be used cautiously in disease states because Acta2 is expressed by non-SMC in diseased vessels. 38, 39 A new aspect of our study, as concerns characterization of these SMC-Cre alleles, is our finding of background (tamoxifen independent) Cre activity in both vascular and nonvascular SMC. This has not been reported by others 27, 39 and should be accounted for in experimental designs, especially when clonal gene deletion could yield an important phenotype. 41 Our results address the question of whether SMC TGF-β signaling is pathogenic or protective of aortic disease. This question is important because current clinical trials are based on the premise that TGF-β signaling is pathogenic. 22, 23 If this premise is incorrect, these trials are unlikely to have positive outcomes. Arguments that TGF-β signaling in SMC is pathogenic are based on finding elevated pSMAD-2 in human aneurysmal tissue and in mouse models of human aortopathy 17, 20, 42 ; however, it is uncertain whether this finding is a cause or an effect of aortopathy, 43 and pSMAD-2 can be increased via pathways independent of TGF-β. 44 Moreover, elevated pSMAD-2 in diseased human aortas is not physically associated with TGF-β ligand accumulation, arguing that TGF-β is not the cause of pSMAD-2 upregulation. 16 Proponents of the TGF-β-driven aortopathy hypothesis bolster their arguments by pointing to a tissue signature of increased TGF-β signaling in diseased human and mouse aortas: elevated expression of connective tissue growth factor, collagen, and PAI-1 (plasminogen activator inhibitor type 1). 20, 42, 45 However, the absence of this signature in diseased aortas is not accepted as evidence that TGF-β activity is not elevated, and therefore not pathogenic. 19 Our results support a protective role for SMC TGF-β signaling by showing conclusively that physiological SMC TGF-β signaling is required for postnatal aortic homeostasis and that disrupting SMC TGF-β signaling causes severe aortic pathology: IMH, PAU, dilation, and dissection. These results are consistent with other reports of salutary roles for TGF-β signaling in the aortic wall, 14, 15, 24, 46 and decrease enthusiasm for human therapies that target aortic TGF-β signaling.
Our experiments were performed in young mice, raising concern that they may not apply to adult mice or humans. 47 This concern is consistent with a recent report that systemic neutralization of TGF-β in Fbn1-deficient mice worsens aortopathy in young mice but prevents aortopathy in older mice. 48 This report and the observation that deletion of SMC Tgfbr2 causes aortic dissection in younger but not in older mice 24 suggests that TGF-β inhibition may be dangerous in youth but protective later on. 47 In a smaller study, however, we found serious aortic pathology (IMH and PAU) in a majority (70%) of mice (n=10) in which SMC Tgfbr2 deletion was induced at 11 to 19 weeks of age (ie, well into adult life; Figure VIIIA and VIIID in the online-only Data Supplement and data not shown). This result (in which the prevalence of aortic pathology is likely underestimated because the aortas were sectioned less extensively than in this study) suggests that inhibition of physiological SMC TGF-β signaling may be unsafe at any age.
Our study does not identify the precise pathways through which loss of TBRII in aortic SMC causes aortopathy; however, it does provide some clues. Our in vitro studies show that SMC loss of TBRII causes rapid loss of both canonical and noncanonical TGF-β signaling pathways, and significant alterations in SMC gene expression. Analyses of aortic medial RNA reveal that altered SMC gene expression persists for at least 4 weeks after Tgfbr2 deletion, and it is accompanied by gross and microscopic evidence of medial and endothelial damage: loss of endothelial barrier function leading to entry of blood into the media, loss of medial cell cohesiveness leading to ulceration and dissection, and medial elastolysis. Loss of barrier function, medial cell cohesiveness, and elastolysis are all plausible sequelae of the alterations in SMC gene expression that we describe: increased matrix metalloprotease expression and dysregulation of SMC contractile proteins. Medial thickening at 4 weeks could be because of SMC hypertrophy, edema because of increased permeability, macrophage infiltration, IMH that have partially resolved, or a combination of these processes. Because cell proliferation affects only a small minority of medial cells, medial cell proliferation seems to play a minor role. Aortic dilation and PAU 14 weeks after SMC loss of TBRII are likely because of persistent medial SMC dysfunction. Increased Mac-2 abundance throughout the vessel wall and enhanced matrix deposition and cell proliferation in the adventitia probably reflect compensatory healing responses to medial SMC dysfunction. According to this model ( Figure XVI in the online-only Data Supplement), aortopathy in mice with SMC-specific loss of TBRII is driven by cell-autonomous events in medial SMC. This model is supported by our in vitro data showing significant changes in aortic SMC gene expression after loss of TBRII, in the absence of exposure to other cell types.
In both the in vitro and in vivo studies presented here, loss of SMC TBRII caused upregulation of SMC expression of TGF-β signaling components: ligands, receptors, and a regulator of canonical TGF-β signaling (Smad7). These findings raise the possibility that compensatory, cell-autonomous upregulation of TGF-β signaling occurs after loss of TBRII, as reported in murine palatal mesenchymal cells with Tgfbr2 deletion. 49 Upregulation of TGF-β signaling in TBRII-null SMC-if present-would be congruent with reports of paradoxical upregulation of TGF-β signaling in humans with lossof-function mutations in TGF-β signaling components. 20, 42, 50 This paradoxical upregulation of TGF-β signaling is thought to drive these human aortopathies and could potentially explain aortopathy in this study. SMC upregulation of Myh11, Tagln, and Acta2 mRNA would be consistent with increased TGFβ signaling. However, our data are inconsistent with simple upregulation of either canonical or noncanonical TGF-β signaling. In vitro, TBRII-null SMC seems to lose both canonical and noncanonical signaling in response to TGF-β ligand. In vivo, we found no evidence that loss of TBRII leads to upregulated expression of well-established TGF-β-responsive genes (Col1a1, Ctgf, and Serpine1). In summary, although TGF-β signaling components are upregulated after SMC-specific loss of TBRII, it is unclear whether SMC TGF-β signaling increases, and if so, whether this drives the aortopathy or is an epiphenomenon.
While this study was in progress, another group reported the use of the Myh11-CreER T2 allele to delete a different Tgfbr2 exon (exon 2) in postnatal mice. 24 Both studies found that SMC loss of TBRII in young mice causes aortopathy with early-medial thickening, elastin fragmentation, adventitial fibrosis and proliferation, as well as later medial atrophy and aortic dilation. Both studies also found elevated Tgfb2 and Tgfb3 mRNA after Tgfbr2 deletion in vivo as well as loss of both canonical and noncanonical TGF-β signaling in vitro in SMC lacking TBRII. Our study adds new information by including a more detailed histological characterization of the aortopathy (including a small study in older mice), by characterizing aberrant SMC gene expression that occurs early after loss of TBRII (in vitro), by focusing our in vivo gene expression studies on aortic media, and by including females (≈50% of Acta2-Cre +/0 mice). Our novel findings include (1) the aortopathy includes the AA and is least pronounced in the DTA (regional variability of aortic pathology could potentially be because of variations in the embryonic origin of SMC, with AscA SMC derived from neural crest, DTA SMC from somites, and abdominal aortic SMC from mesoderm) 51 ;
(2) aortopathy is common after SMC Tgfbr2 deletion in older mice; (3) mRNA encoding SMC contractile proteins are upregulated in the aortic media (and in cultured SMC) after Tgfbr2 deletion, whereas Col1a1 is not upregulated; (4) evidence of leukocytic infiltration is not limited to the adventitia; (5) cell proliferation after loss of SMC Tgfbr2 occurs predominantly in the adventitia; and (6) aortic hematomas and dissections seem confined to the early period after Tgfbr2 deletion and resolve over time. Moreover, our in vitro gene expression data suggest that SMC dysfunction and upregulated matrix metalloprotease expression occur early after SMC loss of TBRII. When combined with the modest effect of TBRII loss on medial proliferation, our data support SMC dysfunction as a primary cause of aortopathy after loss of TBRII, and tend to discount a critical role for adventitial growth factor-driven proliferative medial disease. 24 Loss-of-function mutations in TGFBR2 cause aortopathy in humans, 42, 52 raising the question of whether our data provide mechanistic insight into this human disease. We think our data to provide insight, but with a caveat. Specifically, our finding that disruption of SMC TGF-β signaling causes SMC dysfunction and aortopathy identifies SMC dysfunction as a probable cause of aortic disease in humans with TGFBR2 mutations. However, we are hesitant to derive mechanistic insights beyond this, because the TGFBR2 mutants that cause human aortic disease are not null alleles 42, 52, 53 and it is uncertain to what extent acute homozygous receptor knockout can model a disease that is caused by the lifelong presence of heterozygous mutant receptors. The most important application of this study to human health is the unambiguous lesson that physiological TGF-β signaling is vital for postnatal aortic health. Strategies aimed at blocking TGF-β signaling in humans should take this into account.
